Emtricitabine + tenofovir alafenamide

1. Emtricitabine + tenofovir alafenamide decreases IL-6 in humans (-0.058, p=0.029).

   “with significant reductions in epigenetic IL-6 (-0.058, p=0.029)”

   Human trialhealthy people without HIV200 mg/25 mg12 weeksn = 36

   An FDA-Approved Tenofovir Alafenamide-Based Antiretroviral Therapy Reduces Biological Age in Healthy Adults: First Human Proof-of-Concept for Retrotransposon-Targeted Gerotherapeutics

   medRxiv : the preprint server for health sciences·26 Mar 2026Preprint

More on IL-6

1. Emtricitabine + tenofovir alafenamide decreases PhenoAge in humans (-6.33, p=0.008).

   “PhenoAge (-6.33, p=0.008), with concordant reductions (p<0.05) across additional systems-specific epigenetic clocks”

   Human trialhealthy people without HIV200 mg/25 mg12 weeksn = 36

   An FDA-Approved Tenofovir Alafenamide-Based Antiretroviral Therapy Reduces Biological Age in Healthy Adults: First Human Proof-of-Concept for Retrotransposon-Targeted Gerotherapeutics

   medRxiv : the preprint server for health sciences·26 Mar 2026Preprint

More on PhenoAge

1. Emtricitabine + tenofovir alafenamide decreases DunedinPACE in humans (-0.061, p=0.019).

   “In the FTC/TAF study (N=36), epigenetic aging measures based on DNA methylation (DNAm) profiling decreased over follow-up, including DunedinPACE (-0.061, p=0.019)”

   Human trialhealthy people without HIV200 mg/25 mg12 weeksn = 36

   An FDA-Approved Tenofovir Alafenamide-Based Antiretroviral Therapy Reduces Biological Age in Healthy Adults: First Human Proof-of-Concept for Retrotransposon-Targeted Gerotherapeutics

   medRxiv : the preprint server for health sciences·26 Mar 2026Preprint

More on DunedinPACE